<DOC>
	<DOC>NCT02555800</DOC>
	<brief_summary>The aim of this study is to compare the efficacy of intralesional bevacizumab, a monoclonal antibody against vascular endothelial growth factor, versus the antiviral drug cidofovir in patients with recurrent respiratory papillomatosis.</brief_summary>
	<brief_title>Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis</brief_title>
	<detailed_description>The investigators designed a randomized, double-blind, placebo-controlled study. Children and adults will be randomized to receive either 3 dosis of intralesional bevacizumab, cidofovir or saline solution. Primary endpoints are the assessment of changes in the annual surgery rate and Derkay papilloma severity grading scale; secondary endpoints are changes in the Voice Handicap Index and safety.</detailed_description>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Patients diagnosed with recurrent respiratory papillomatosis proven by biopsy. Patients with 2 or more previous surgeries for papillomatosis Patients with heart or renal disease Patients who receive another adjuvant therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Laryngeal papillomatosis</keyword>
	<keyword>Cidofovir</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Recurrent respiratory papillomatosis</keyword>
</DOC>